A Gel Formulation Containing a New Recombinant Form of Manganese Superoxide Dismutase: A Clinical Experience Based on Compassionate Use-Safety of a Case Report

Figure 1

Lenz of right eye (a) and left eye (b) before the administration, respectively, of rMnSOD gel formulation in the right eye (c) and left eye (d) after the treatment with Bendazac-lysine g 0.5 eye drops.

(a)

(b)

(c)

(d)